Collaboration to Investigate IBD Candidates

Numab Therapeutics AG (Numab) has announced a collaboration and option agreement with Kaken Pharmaceutical for the identification of a multispecific antibody candidate for development in

inflammatory disease. Under the agreement, Kaken, a Japanese company with strong experience in developing and commercialising novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its multispecific antibody technology platform. Kaken is to fully fund the research program. Further financial details are not disclosed.

Founded in 2011, Numab develops a proprietary pipeline of multi specific biotherapeutics in immunooncology and immunology and has a numberof discovery partnerships with pharmaceutical companies. The company is represented in Japan by PharmaBDL